Management Team & Advisors

Heyward Coleman MBA

CHIEF EXECUTIVE OFFICER

Heyward Coleman MBA
Heyward Coleman is the Chief Executive Officer and a founding member of Viewpoint Molecular Targeting, LLC, an Iowa company formed in 2008 to develop new pharmaceuticals for imaging and therapy of cancer. Mr. Coleman brings a mix of technical understanding and practical technology start up financial management experience.Mr Coleman earned a Master of Science Degree in Nuclear Engineering from Duke University and a Master of Business Administration from Harvard University. After a successful career in the oil and gas business, Mr. Coleman became a serial entrepreneur, and founded what became the largest privately owned radiochemistry company in the United States and has been a principal in two other successful biomedical technology startup enterprises.Mr Coleman is responsible for overseeing operating agreements, licensing, financial statements and taxes. Mr Coleman is also skilled in the art of Term Sheet development and this skill will be crucial to success as the company grows and products develop into licensing candidates and further spin-out entities.

Michael K Schultz PhD

CHIEF SCIENCE OFFICER

Michael K Schultz PhD

Michael Schultz PhD is a founding member and Chief Science Officer of Viewpoint Molecular Targeting, LLC. Dr. Schultz is also an Assistant Professor in the College of Medicine at the University of Iowa. Dr. Schultz specializes in molecular targeting for diagnostic imaging and cancer therapy and is primary and co-inventor of Viewpoint IP. Dr. Schultz has been involved as a leader at the UI for the submission of successful INDs to the FDA for molecular diagnostics, led the technical development of the first gallium-68 radiolabeled peptide for clinical human studies in the United States and worked as a consultant to a large pharmaceutical company for a successful IND for a radiopharmaceutical for cancer therapy.

In addition, Dr. Schultz brings five years of experience as a high technology business manager, where he managed a $20M per year high technology product line including R&D, product management, marketing, and sales.

Frances Johnson MD

CHIEF MEDICAL OFFICER

Frances Johnson MD

Frances Johnson MD, Associate Professor of Internal Medicine is a founding member and Chief Medical Officer of Viewpoint. Dr Johnson trained in medicine at the University of Washington, with a residency at the University of California, San Francisco, and fellowship, which led to a tenure track appointment at Stanford University. During her time at Stanford, Dr Johnson was involved as an inventor and investor in two previous biotech startups including XDx, Inc., which is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to manage the care of heart transplant patients.

Dr. Johnson is experienced in clinical trial design and commercialization of biotech discoveries for human diagnostic imaging and therapy.

Michael Graham MD PhD

ADVISORY BOARD MEMBER

Michael Graham MD PhD

Dr. Graham is Professor and Vice Chair of Radiology and Director of Nuclear Medicine at the University of Iowa. He does clinical nuclear medicine and PET imaging, directs the nuclear medicine residency training program, is involved in several research initiatives, and is very active nationally in the Society of Nuclear Medicine.

Dr. Graham received a BSEE from MIT, MSEE from UC Berkeley, PhD in Biophysics from UC Berkeley, and MD from UCSF. He trained in internal medicine and nuclear medicine at the University of Washington in Seattle, and is board-certified in both areas. In 1980 he joined the faculty at UW.

He was involved in PET research at the UW since its inception in the early 1980s and moved to the University of Iowa in October, 1999. At the University of Washington he was PI of an R01 “Modification of Radiation-Induced Vascular Permeability” for 7 years. He was also PI of an oncology based PET program project “Metabolic Imaging of Cancer and its Response to Therapy” for 5 years and was PI of an RO1 “PET Imaging of Esophageal Cancer Response to Therapy”, which was moved to the University of Iowa. At the University of Washington, as part of the PET research group, Dr. Graham’s major contribution was in quantitative data analysis, particularly of 18F-FDG and 11C-glucose to determine the FDG lumped constant in-vivo. He also was a major contributor in kinetic modeling analysis of 18F-fluoromisonidazole, 11C-thymidine, and 15O-water for blood flow.

At the end of 1999 he moved to the University of Iowa, where he is currently a Professor and Vice Chair of Radiology and is Director of Nuclear Medicine, including PET and small animal imaging. He is team leader of the Image Response Assessment Team (IRAT) and is head of the Tumor Imaging Program as part of the Holden Comprehensive Cancer Center. He obtained a pre-ICMIC (In-vivo Cellular and Molecular Imaging Center) NCI grant which allowed creation of the small animal imaging center. He also obtained funding for a GE Hawkeye SPECT-CT system as a supplemental grant to the Cancer Center. He is past chair of the Radiology Performance Improvement Committee and is a member of the Radiation Protection and Diagnostic Services committees. He is Program Director of the nuclear medicine residency program, currently with 2 residents.

Dr. Graham has been active nationally in the Society of Nuclear Medicine (President of the Computer Council, President of the Brain Imaging Council, President of the Academic Council, President of the Northwest Chapter, member of the Board of Trustees for over 10 years, past member of the Board of Directors, President of SNM, and currently is President of the Missouri Valley Chapter). At NIH he has served on several site visit review committees and on several NIH grant review committees, including R-21 grants. He was a regular member of study section NCI-F (T32 and K awards) for 4 years, including ad-hoc for 10 years. He was also chair of an NIH study section for R21 quick trials involving medical imaging. He has participated in several NIH workshops including meetings on FDG quantitation, therapy of colon cancer, angiogenesis imaging, and comparative effectiveness research. He is past chair of the American Board of Nuclear Medicine and also past chair of the ACGME Resident Review Committee for Nuclear Medicine. His CV currently contains 178 papers, 9 chapters and 141 abstracts.

Strategic Partners

Viewpoint is aligned with strategic partners that synergize to accelerate the process of drug development and clinical translation of new products.

Contact & Investors

Viewpoints products are founded on years of funded academic research on fundamental differences in cancer cells and cancerous tumors compared to healthy normal cells. Viewpoint seeks out partnerships that can add energy to its efforts to accelerate these discoveries to new improved diagnostic agents and therapies for patient care.